Back
Alkermes PLC 10K Form
Buy
53
ALKS
Alkermes PLC
Last Price:
24.69
Seasonality Move:
5.6%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-10-25 | 10Q | ALKS/Alkermes PLC Quarterly |
| 2023-07-26 | 10Q | ALKS/Alkermes PLC Quarterly |
| 2023-04-26 | 10Q | ALKS/Alkermes PLC Quarterly |
| 2022-11-02 | 10Q | ALKS/Alkermes PLC Quarterly |
| 2022-07-27 | 10Q | ALKS/Alkermes PLC Quarterly |
| 2022-04-27 | 10Q | ALKS/Alkermes PLC Quarterly |
Receive ALKS News And Ratings
See the #1 stock for the next 7 days that we like better than ALKS
ALKS Financial Statistics
Sales & Book Value
| Annual Sales: | $1.66B |
|---|---|
| Cash Flow: | $90.21M |
| Price / Cash Flow: | 11.8 |
| Annual Sales: | $7.20 |
| Price / Book: | 3.43 |
Profitability
| EPS (TTM): | 2.07000 |
|---|---|
| Net Income (TTM): | $355.76M |
| Gross Margin: | $1.41B |
| Return on Equity: | 30.21% |
| Return on Assets: | 16.96% |
Alkermes PLC Earnings Forecast
Key Alkermes PLC Financial Ratios
- The Gross Profit Margin over the past 32 years for ALKS is 84.79%.
- The Selling, General & Administrative Expenses for ALKS have been equal to 41.47% of Gross Profit Margin.
- The Research & Development expenses have been 16.28% of Revenue.
- The Interest Expense is 6.47% of Operating Income.
- The Net Earning history of ALKS is 21.39% of Total Revenues.
- Per Share Earnings over the last 32 years have been positive in 16 years.
Alkermes PLC Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ALKS |
| CUSIP: | G01767 |
| Website: | alkermes.com |
Debt
| Debt-to-Equity Ratio: | 0.24 |
|---|---|
| Current Ratio: | 2.86 |
| Quick Ratio: | 2.13 |
Price-to-Earnings
| Trailing P/E Ratio: | 11.75 |
|---|---|
| Forward P/E Ratio: | 9.85 |
ALKS Technical Analysis vs Fundamental Analysis
Buy
53
Alkermes PLC (ALKS)
is a Buy
Is Alkermes PLC a Buy or a Sell?
-
Alkermes PLC stock is rated a Buy
The current Alkermes PLC [ALKS] share price is $24.68. The Score for ALKS is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.